Business Wire06.26.18
Dune Medical Devices has appointed Alan Bond as chief financial officer. Bond is a veteran financial executive with an extensive record of developing and implementing strategy, and driving revenue and profitability in the medical device industry. Bond joins the Dune Atlanta (Ga.) office after years with McKesson and Given Imaging.
“Alan has experience in both large and small organizations during times where the companies were undergoing significant strategic changes and acquisitions,” said Lori Chmura, CEO of Dune Medical. “His experience in driving organizational performance will add significantly to Dune Medical’s capability to manage new growth, and we are pleased to add him to our distinguished team.”
Dune Medical Devices’ proprietary tissue characterization technology utilizing Radiofrequency (RF) Spectroscopy, is a solution to identifying microscopic residual cancer at the surface of the tissue to give surgeons another tool to help identify all the cancerous tissue in the operating room. Dune’s first medical device, the MarginProbe System, achieved U.S. Food and Drug Administration approval in 2013 for use in breast cancer lumpectomy procedures. Numerous peer-reviewed publications have demonstrated a 50 percent to 79 percent reduction in re-excision with the use of MarginProbe.
“Breast conservation surgery is a first line surgical modality for most women facing a breast cancer diagnosis and MarginProbe improves the effectiveness and outcome of the surgery,” said Bond. “I look forward to playing an important role in optimizing Dune’s organizational performance and bringing a strategic focus as we expand our revolutionary technology platform to the diagnosis, surgery and therapy of other cancers.”
Dune Medical Devices develops, manufactures, and commercializes products that improve the effectiveness and outcome of cancer therapy by providing real-time tissue characterization systems to guide surgical and diagnostic decisions. It is a privately held company with offices in the U.S. (Alpharetta, Ga.) and Israel.
“Alan has experience in both large and small organizations during times where the companies were undergoing significant strategic changes and acquisitions,” said Lori Chmura, CEO of Dune Medical. “His experience in driving organizational performance will add significantly to Dune Medical’s capability to manage new growth, and we are pleased to add him to our distinguished team.”
Dune Medical Devices’ proprietary tissue characterization technology utilizing Radiofrequency (RF) Spectroscopy, is a solution to identifying microscopic residual cancer at the surface of the tissue to give surgeons another tool to help identify all the cancerous tissue in the operating room. Dune’s first medical device, the MarginProbe System, achieved U.S. Food and Drug Administration approval in 2013 for use in breast cancer lumpectomy procedures. Numerous peer-reviewed publications have demonstrated a 50 percent to 79 percent reduction in re-excision with the use of MarginProbe.
“Breast conservation surgery is a first line surgical modality for most women facing a breast cancer diagnosis and MarginProbe improves the effectiveness and outcome of the surgery,” said Bond. “I look forward to playing an important role in optimizing Dune’s organizational performance and bringing a strategic focus as we expand our revolutionary technology platform to the diagnosis, surgery and therapy of other cancers.”
Dune Medical Devices develops, manufactures, and commercializes products that improve the effectiveness and outcome of cancer therapy by providing real-time tissue characterization systems to guide surgical and diagnostic decisions. It is a privately held company with offices in the U.S. (Alpharetta, Ga.) and Israel.